<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-19T15:52:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/11800" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/11800</identifier><datestamp>2025-10-24T10:37:07Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy</dc:title>
   <dc:creator>Pasquali, Sandro</dc:creator>
   <dc:creator>Vallacchi, Viviana</dc:creator>
   <dc:creator>Lalli, Luca</dc:creator>
   <dc:creator>Collini, Paola</dc:creator>
   <dc:creator>Barisella, Marta</dc:creator>
   <dc:creator>Romagosa, Cleofé</dc:creator>
   <dc:subject>Sarcoma - Tractament</dc:subject>
   <dc:subject>Tumors de parts toves - Tractament</dc:subject>
   <dc:subject>Limfòcits</dc:subject>
   <dc:subject>Avaluació de resultats (Assistència sanitària)</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::Other subheadings::/drug therapy</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy</dc:subject>
   <dc:subject>DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma</dc:subject>
   <dc:subject>ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de los tejidos blandos</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante</dc:subject>
   <dc:subject>ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::sarcoma</dc:subject>
   <dc:subject>ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos infiltrantes de tumor</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento</dc:subject>
   <dcterms:abstract>Anthracycline; Neoadjuvant chemotherapy; Soft tissue sarcomas</dcterms:abstract>
   <dcterms:abstract>Antraciclina; Quimioterapia neoadyuvante; Sarcomas de tejidos blandos</dcterms:abstract>
   <dcterms:abstract>Antraciclina; Quimioteràpia neoadjuvant; Sarcomes de teixits tous</dcterms:abstract>
   <dcterms:abstract>Background: Anthracycline-based neoadjuvant chemotherapy (NAC) may modify tumour immune infiltrate. This study characterized immune infiltrate spatial distribution after NAC in primary high-risk soft tissue sarcomas (STS) and investigate association with prognosis.&#xd;
Methods: The ISG-STS 1001 trial randomized STS patients to anthracycline plus ifosfamide (AI) or a histology-tailored (HT) NAC. Four areas of tumour specimens were sampled: the area showing the highest lymphocyte infiltrate (HI) at H&amp;E; the area with lack of post-treatment changes (highest grade, HG); the area with post-treatment changes (lowest grade, LG); and the tumour edge (TE). CD3, CD8, PD-1, CD20, FOXP3, and CD163 were analyzed at immunohistochemistry and digital pathology. A machine learning method was used to generate sarcoma immune index scores (SIS) that predict patient disease-free and overall survival (DFS and OS).&#xd;
Findings: Tumour infiltrating lymphocytes and PD-1+ cells together with CD163+ cells were more represented in STS histologies with complex compared to simple karyotype, while CD20+ B-cells were detected in both these histology groups. PD-1+ cells exerted a negative prognostic value irrespectively of their spatial distribution. Enrichment in CD20+ B-cells at HI and TE areas was associated with better patient outcomes. We generated a prognostic SIS for each tumour area, having the HI-SIS the best performance. Such prognostic value was driven by treatment with AI.&#xd;
Interpretation: The different spatial distribution of immune populations and their different association with prognosis support NAC as a modifier of tumour immune infiltrate in STS.</dcterms:abstract>
   <dcterms:abstract>Pharmamar; Italian Ministry of Health [RF-2019-12370923; GR-2016-02362609]; 5 × 1000 Funds—2016, Italian Ministry of Health; AIRC Grant [ID#28546].</dcterms:abstract>
   <dcterms:dateAccepted>2025-10-24T10:37:07Z</dcterms:dateAccepted>
   <dcterms:available>2025-10-24T10:37:07Z</dcterms:available>
   <dcterms:created>2025-10-24T10:37:07Z</dcterms:created>
   <dcterms:issued>2024-07-31T08:20:05Z</dcterms:issued>
   <dcterms:issued>2024-07-31T08:20:05Z</dcterms:issued>
   <dcterms:issued>2024-07-16</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>http://hdl.handle.net/11351/11800</dc:identifier>
   <dc:relation>eBioMedicine;106</dc:relation>
   <dc:relation>https://doi.org/10.1016/j.ebiom.2024.105220</dc:relation>
   <dc:rights>Attribution-NonCommercial 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>Elsevier</dc:publisher>
   <dc:source>Scientia</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>